ASX-listed Kiwi company Volpara Health Technologies has entered into a research and development collaboration with Microsoft to accelerate developing a product that detects and quantifies breast arterial calcifications (BACs).
BACs have been shown to be associated with cardiovascular problems and
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
